WO2002024745A3 - Verfahren zum nachweis von tumorzellen - Google Patents

Verfahren zum nachweis von tumorzellen Download PDF

Info

Publication number
WO2002024745A3
WO2002024745A3 PCT/EP2001/010831 EP0110831W WO0224745A3 WO 2002024745 A3 WO2002024745 A3 WO 2002024745A3 EP 0110831 W EP0110831 W EP 0110831W WO 0224745 A3 WO0224745 A3 WO 0224745A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna
tumor cells
double
strand
detecting tumor
Prior art date
Application number
PCT/EP2001/010831
Other languages
English (en)
French (fr)
Other versions
WO2002024745A2 (de
Inventor
Hinrich Abken
Timo Schinkoethe
Original Assignee
Hinrich Abken
Timo Schinkoethe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hinrich Abken, Timo Schinkoethe filed Critical Hinrich Abken
Priority to AU2001287744A priority Critical patent/AU2001287744A1/en
Publication of WO2002024745A2 publication Critical patent/WO2002024745A2/de
Publication of WO2002024745A3 publication Critical patent/WO2002024745A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zum Nachweis von Tumorzellen, bei dem man ausserhalb des Zellkerns einer Zelle eine DNA nachweist, die aus einem Strang besteht und eine doppelsträngige Struktur aus mindestens vier Basenpaaren, die einen Doppelstrang bilden (Stamm), und einer den Stamm verbindenden einsträngigen Schleife (Loop) aus höchstens 15 Basen aufweist, wobei die doppelsträngige Struktur mindestens eine Bindestelle für DNA-bindende Proteine aufweist. Die Erfindung betrifft weiterhin Substanzen, die für das erfindungsgemässe Nachweisverfahren geeignet sind, sowie Kits und Arzneimittel.
PCT/EP2001/010831 2000-09-19 2001-09-19 Verfahren zum nachweis von tumorzellen WO2002024745A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001287744A AU2001287744A1 (en) 2000-09-19 2001-09-19 Method for detecting tumor cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10046318.5 2000-09-19
DE10046318A DE10046318A1 (de) 2000-09-19 2000-09-19 Verfahren zum Nachweis von Tumorzellen

Publications (2)

Publication Number Publication Date
WO2002024745A2 WO2002024745A2 (de) 2002-03-28
WO2002024745A3 true WO2002024745A3 (de) 2003-10-23

Family

ID=7656773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/010831 WO2002024745A2 (de) 2000-09-19 2001-09-19 Verfahren zum nachweis von tumorzellen

Country Status (3)

Country Link
AU (1) AU2001287744A1 (de)
DE (1) DE10046318A1 (de)
WO (1) WO2002024745A2 (de)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576862A2 (de) * 1992-06-10 1994-01-05 Roche Diagnostics GmbH DNA zur Immortalisierung von humanen oder tierischen Zellen
WO1995002701A1 (de) * 1993-07-15 1995-01-26 Boehringer Mannheim Gmbh Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
WO1999018235A1 (de) * 1997-10-07 1999-04-15 Hinrich Abken Verfahren zum nachweis sowie zur gewinnung oder beseitigung von human- oder säugerzellen mit gestörter zellzykluskontrolle ode r der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
EP0955383A1 (de) * 1998-03-25 1999-11-10 The University Of Manitoba Verfahren und Marker zur Identifizierung der Präe-Malignität und Malignität und deren Verwendung bei der therapeutischen Behandlung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576862A2 (de) * 1992-06-10 1994-01-05 Roche Diagnostics GmbH DNA zur Immortalisierung von humanen oder tierischen Zellen
WO1995002701A1 (de) * 1993-07-15 1995-01-26 Boehringer Mannheim Gmbh Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
WO1999018235A1 (de) * 1997-10-07 1999-04-15 Hinrich Abken Verfahren zum nachweis sowie zur gewinnung oder beseitigung von human- oder säugerzellen mit gestörter zellzykluskontrolle ode r der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
EP0955383A1 (de) * 1998-03-25 1999-11-10 The University Of Manitoba Verfahren und Marker zur Identifizierung der Präe-Malignität und Malignität und deren Verwendung bei der therapeutischen Behandlung

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ABKEN H ET AL: "Short DNA sequences from the cytoplasm of mouse tumor cells induce immortalization of human lymphocytes in vitro", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, 1 July 1993 (1993-07-01), pages 6518 - 6522, XP002095019, ISSN: 0027-8424 *
CHMIELEWSKI J ET AL: "MONOCLONAL ANTIBODIES WITH SEQUENCE SPECIFIC AFFINITY FOR A STEM-LOOP STRUCTURE IN DNA", TETRAHEDRON, vol. 47, no. 14-15, 1991, pages 2563 - 2572, XP002219218, ISSN: 0040-4020 *
COLLINS V: "Gene amplification in human gliomas", GLIA, WILEY-LISS, NEW YORK, NY, US, vol. 15, no. 3, November 1995 (1995-11-01), pages 289 - 296, XP002109702, ISSN: 0994-1491 *
DATABASE EBI [online] EMBL; 26 January 2000 (2000-01-26), ABKEN, HINRICH: "Sequence 31 from Patent WO9918235", XP002219160, retrieved from EBI accession no. A97185 Database accession no. A97185 *
HEGGER R AND ABKEN H: "The short DNA sequences in the cytoplasm of Ehrlich ascites tumor cells are tightly associated with proteins", PHYSIOLOGICAL CHEMISTRY AND PHYSICS AND MEDICAL NMR, XX, US, vol. 27, no. 4, 1995, pages 321 - 328, XP002095017, ISSN: 0748-6642 *
LEWIN, BENJAMIN: "Genes V", 1994, OXFORD UNIVERSITY PRESS, WALTON STREET, OXFORD;, XP002219159 *
WILHELM M L ET AL: "Transfer RNA binding protein in the nucleus of Saccharomyces cerevisiae.", FEBS LETTERS, vol. 349, no. 2, 1994, pages 260 - 264, XP002219219, ISSN: 0014-5793 *

Also Published As

Publication number Publication date
WO2002024745A2 (de) 2002-03-28
AU2001287744A1 (en) 2002-04-02
DE10046318A1 (de) 2002-03-28

Similar Documents

Publication Publication Date Title
AU2001234760A1 (en) Rolling circle amplification assay for nucleic acid analysis
CA2256545A1 (en) Probe for analysis of nucleic acids
ZA200107497B (en) Methods for detection of nucleic acid polymorphisms using peptide-labeled oligonucleotides and antibody arrays.
WO2002002817A3 (en) Multipartite high-affinity nucleic acid probes
WO2005052542A3 (en) Method and composition useful for determining fk 506
WO2001075767A3 (en) In silico cross-over site selection
AU3701900A (en) Analytical methods and materials for nucleic acid detection
WO2002038806A3 (de) Nachweis von nukleinsäure-polymorphismen
EP1035215A3 (de) Verfahren und Sondenset zur Erkennung von Krebs
WO2002077604A3 (en) Labeled cells for use as an internal functional control in rare cell detection assays
WO2003033722A3 (en) Nucleic acid amplification methods
AU2001271438A1 (en) Method for separation, identification and evaluation of microbes and cells
WO2001083814A3 (en) Assay for nucleic acid analysis
WO2001034824A3 (en) Methods and compositions comprising renilla gfp
WO2002033402A3 (en) Establishment of biological cut-off values for predicting resistance to therapy
WO2005001142A3 (en) Methods and nucleic acids for the analysis of colorectal cell proliferative disorders
WO2005001141A3 (en) Methods and nucleic acids for analyses of colorectal cell proliferative disorders
WO2003078603A3 (en) Strong gene sets for glioma classification
EP1283272A3 (de) Verfahren und Mittel zur Bewertung einer HIV Hülleninhibitortherapie
AU1114601A (en) Group of novel primer pairs for PCR amplification, primer pairs, gene probes and method for detecting technically genetically modified plant material
WO2001062965A3 (en) Differential expression screening method
WO2002024745A3 (de) Verfahren zum nachweis von tumorzellen
EP1098003A3 (de) Verfahren zur Identifizierung und spezifischen Detektion langsam wachsender Mycobakterien unter Verwendung des Gens für DNA Gyrase
WO2003031612A3 (en) Method for determining cell cycle position
WO2002006802A3 (en) Screening crystallisation conditions of organic compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP